Assessment of OSA in Latin American and Response to Neuromod Therapy

NCT06762873 | Recruiting Early Phase 1

• 1 other identifier: 10081
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to characterize the upper airway of Latin American subjects who have been diagnosed with moderate/severe obstructive sleep apnea (OSA) and assess response to a neuromodulation therapy to treat OSA.

Conditions

Obstructive Sleep Apnea

Outcome Measures

Primary Outcomes (3)

• Understand the difference in response compared to prior U.S. based studies to the response in Latin America.

  Reviewing phrenic nerve stimulation response to literature of US based population

  enrollment to study exit, usually within 3 weeks of screening

• Use VOTE scoring to characterize the type of upper airway collapse as assessed via DISE.

  Upper Airway will be characterized using VOTE scoring as assessed by a qualified, trained Independent Reviewer.

  enrollment to study exit, usually within 3 weeks of screening

• Use VOTE scoring and airway opening measurements to characterize the effect of Phrenic Nerve Stimulation and if it is a viable and effective treatment of OSA and correlation to phenotype.

  In combination with VOTE scoring and airway opening measurements, the effects of phrenic nerve stimulation will be compared across treated patient population.

  enrollment to study exit, usually within 3 weeks of screening

Study Arms (1)

Trans-Q DISE treated subjects

EXPERIMENTAL

Diagnostic Test: Drug Induced Sleep Endoscopy with PNS

Interventions

Drug Induced Sleep Endoscopy with PNS DIAGNOSTIC_TEST

Enrolled subjects will complete an overnight PSG and then undergo a DISE procedure with a 30-minute research period.

Trans-Q DISE treated subjects

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject is aged ≥ 18 years old
• Subject is willing and able to provide informed consent
• Subject is geographically stable
• Subject does not have access to alternative Sleep Disordered Breathing treatments (e.g. oral appliances, and/or behavioral treatments)
• Subject has an Apnea-Hypopnea Index (AHI) score ≥15 \< 100 events per hour on Screening PSGs (under AASM 4%) based on in-lab polysomnography studies

You may not qualify if:

• Subject is currently implanted with another active implantable device.
• Subject is actively enrolled in another premarket investigational study (medical device or drug) unless approved by Sponsor in writing.
• Subject is considered vulnerable such as incarcerated or cognitively impaired.
• Subject is taking opioids, narcotics, sleep or psychotic medications or supplements that in the opinion of the investigator may alter consciousness, the pattern of respiration, sleep architecture, or with known effect on sleep-wake function or alertness.
• Any reason for which, in the judgment of the investigator, the subject is considered to be a poor study candidate, which may include, but is not limited to: any uncontrolled neurological, medical, social, or psychological problems that could complicate the required procedures and evaluations of the study ((e.g. uncontrolled hypertension, unstable angina, uncompensated heart failure or COPD, major depression, Parkinson's disease, epilepsy)
• Subject has previous upper respiratory tract (URT) surgery (e.g., uvula, soft palate or tonsils) within 60 days prior to Screening PSG.
• Subject has a need for chronic supplemental oxygen therapy for any reason or a PaO2 \<70 mm Hg
• Subject has other sleep disorders or sleep hygiene behaviors that confound functional assessments of sleepiness and/or overnight PSG Study outcomes (e.g. Narcolepsy with cataplexy, idiopathic hypersomnolence, insomnia, REM sleep behavior disorder, or sleep movement disorders, such as restless leg syndrome or periodic limb movement, producing sleep disturbances unrelated to OSA.)
• Subject has severe chronic kidney disease (GFR \< 30)
• Subject has currently excessive use of alcohol, tobacco, caffeine, or recreational drugs.
• Subject is unwilling or unable to refrain from consumption of alcoholic beverages for 24 hours prior to the start of each PSG study.
• Subject has a BMI \> 40 kg/m2
• Subject has an active systemic infection
• If female, subject is pregnant at the time of enrollment or planning to become pregnant during the study time period (must have a negative serum or urine pregnancy test within 14 days prior to enrollment)
• Subject has a tonsil size 3 or 4 based on the tonsil grading system

Sponsors & Collaborators

• Lunair Medical: lead

Study Sites (1)

Sanatorio Americano

Asunción, Paraguay

RECRUITING

MeSH Terms

Conditions

Sleep Apnea, Obstructive

Condition Hierarchy (Ancestors)

Sleep Apnea Syndromes; Apnea; Respiration Disorders; Respiratory Tract Diseases; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Nervous System Diseases

Central Study Contacts

Andrea Director of Clinical Operations

CONTACT

866-675-4430; andreas@lunairmedical.com

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 6, 2024
• First Posted: January 8, 2025
• Study Start: November 21, 2024
• Primary Completion: December 31, 2024
• Study Completion: December 31, 2025
• Last Updated: September 3, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)